Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer.

Oncology - 1 Jan 2015

Yamaguchi Takeshi, Mukai Hirofumi, Yamashita Satoshi, Fujii Satoshi, Ushijima Toshikazu

Abstract excerpt

OBJECTIVE: Resistance to trastuzumab is a problem that remains to be solved in HER2-positive breast cancer. We aimed to characterize profiles of genetic and epigenetic alterations in cancer-related pathways in HER2-positive breast cancers, using biopsy tissue samples obtained from patients enrolled in a prospective neoadjuvant clinical trial. METHODS: HER2-positive breast cancer tissue samples were collected and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Methylation
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenomics

Share to Gene Amplification

Share to MAP Kinase Signaling System

Share to Neoplasm Proteins

Share to Receptor, ErbB-2

Share to Wnt Signaling Pathway

Source

Identifiers

PMID: 25591616
DOI: 10.1159/000369904

Genes

CDH1
DKK3
NOTCH1
NOTCH2
SFRP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer.PMID 25591616Read ↗

Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.Semantic proximity Read ↗

Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.Semantic proximity Read ↗

Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.Semantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

Heterogeneity of genomic profile in patients with HER2-positive breast cancer.Semantic proximity Read ↗

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.Semantic proximity Read ↗

"Beyond HER2 overexpression: somatic alterations in HER2 and PI3K genes in HER2-high and HER2-low/TNBC breast cancer.Semantic proximity Read ↗

Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial.Semantic proximity Read ↗

KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.Semantic proximity Read ↗

HER2 mutation as an emerging target in advanced breast cancer.Semantic proximity Read ↗

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.Semantic proximity Read ↗

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.